Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.

Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M

European journal of endocrinology23 Apr 2014Cited by 23 (Europe PMC)

PMID24760537DOI10.1530/eje-13-1013PepBankPUB-24760537

Publisher page PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, CushingQoL change correlated inversely with mUFC change at month 12 (r=-0.40), but not month 6.
In plain wordsIn pasireotide-treated Cushing's disease, changes in quality-of-life scores were inversely linked to changes in urinary cortisol at month 12, but not month 6.
Peptide
Pasireotide
Outcome
DecreaseCushingQoL and mUFC change correlation
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Correlation of change in CushingQoL with change in mUFC
−0.4 r
month 12
Source sentences
Summary
Change in CushingQoL was significantly correlated with changes in mUFC (r=-0.40), BMI (r=-0.39), weight (r=-0.41), and BDI-II (r=-0.54) at month 12 but not at month 6.
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053701
02HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, CushingQoL change correlated inversely with BMI change at month 12 (r=-0.39), but not month 6.
In plain wordsIn pasireotide-treated Cushing's disease, changes in quality-of-life scores were inversely linked to changes in BMI at month 12, but not month 6.
Peptide
Pasireotide
Outcome
DecreaseCushingQoL and BMI change correlation
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Correlation of change in CushingQoL with change in BMI
−0.39 r
month 12
Source sentences
Summary
Change in CushingQoL was significantly correlated with changes in mUFC (r=-0.40), BMI (r=-0.39), weight (r=-0.41), and BDI-II (r=-0.54) at month 12 but not at month 6.
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053702
03HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, CushingQoL change correlated inversely with weight change at month 12 (r=-0.41), but not month 6.
In plain wordsIn pasireotide-treated Cushing's disease, changes in quality-of-life scores were inversely linked to changes in weight at month 12, but not month 6.
Peptide
Pasireotide
Outcome
DecreaseCushingQoL and weight change correlation
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Correlation of change in CushingQoL with change in weight
−0.41 r
month 12
Source sentences
Summary
Change in CushingQoL was significantly correlated with changes in mUFC (r=-0.40), BMI (r=-0.39), weight (r=-0.41), and BDI-II (r=-0.54) at month 12 but not at month 6.
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053703
04HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, CushingQoL change correlated inversely with BDI-II change at month 12 (r=-0.54), but not month 6.
In plain wordsIn pasireotide-treated Cushing's disease, changes in quality-of-life scores were inversely linked to changes in depression scores at month 12, but not month 6.
Peptide
Pasireotide
Outcome
DecreaseCushingQoL and depression change correlation
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Correlation of change in CushingQoL with change in BDI-II
−0.54 r
month 12
Source sentences
Summary
Change in CushingQoL was significantly correlated with changes in mUFC (r=-0.40), BMI (r=-0.39), weight (r=-0.41), and BDI-II (r=-0.54) at month 12 but not at month 6.
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053704
05HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, 63% with controlled mUFC at month 6 were CushingQoL responders at month 12.
In plain wordsIn pasireotide-treated Cushing's disease, 63% with controlled urinary cortisol at month 6 had meaningful quality-of-life improvements at month 12.
Peptide
Pasireotide
Outcome
Not applicableMonth 12 quality-of-life responders, controlled mUFC
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
CushingQoL responders at month 12
63%
controlled mUFC at month 6
Source sentences
Summary
The percentage of CushingQoL responders at month 12 based on month 6 mUFC control status were as follows: 63, 58.8, and 37.9% in the controlled, partially controlled, and uncontrolled groups respectively.
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053705
06HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, 58.8% with partially controlled mUFC at month 6 were CushingQoL responders at month 12.
In plain wordsIn pasireotide-treated Cushing's disease, 58.8% with partially controlled urinary cortisol at month 6 had meaningful quality-of-life improvements at month 12.
Peptide
Pasireotide
Outcome
Not applicableMonth 12 quality-of-life responders, partially controlled mUFC
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
CushingQoL responders at month 12
58.8%
partially controlled mUFC at month 6
Source sentences
Summary
The percentage of CushingQoL responders at month 12 based on month 6 mUFC control status were as follows: 63, 58.8, and 37.9% in the controlled, partially controlled, and uncontrolled groups respectively.
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053706
07HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, 37.9% with uncontrolled mUFC at month 6 were CushingQoL responders at month 12.
In plain wordsIn pasireotide-treated Cushing's disease, 37.9% with uncontrolled urinary cortisol at month 6 had meaningful quality-of-life improvements at month 12.
Peptide
Pasireotide
Outcome
Not applicableMonth 12 quality-of-life responders, uncontrolled mUFC
Study
n: not reported in source
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
CushingQoL responders at month 12
37.9%
uncontrolled mUFC at month 6
Source sentences
Summary
The percentage of CushingQoL responders at month 12 based on month 6 mUFC control status were as follows: 63, 58.8, and 37.9% in the controlled, partially controlled, and uncontrolled groups respectively.
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053707
08HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, controlled patients had adjusted month 12 CushingQoL of 58.3, 11.5 above uncontrolled patients (P=0.012).
In plain wordsIn pasireotide-treated Cushing's disease, controlled patients had higher adjusted quality-of-life scores than uncontrolled patients at month 12.
Peptide
Pasireotide
Outcome
IncreaseAdjusted CushingQoL, controlled versus uncontrolled
Study
n: not reported in source
Comparator
Uncontrolled mUFC at month 6
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Adjusted CushingQoL score
58.3 points
controlled mUFC at month 6, month 12
Difference versus uncontrolled
11.5 points
controlled versus uncontrolled
P value
0.012
controlled versus uncontrolled
Source sentences
Summary
Adjusted CushingQoL scores at month 12 were 58.3 for controlled patients (Δ=11.5 vs uncontrolled, P=0.012) and 54.5 for partially controlled patients (Δ=7.7 vs uncontrolled, P=0.170).
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053708
09HumanObservational studyEfficacy outcome
In pasireotide-treated Cushing's disease, partially controlled patients had adjusted month 12 CushingQoL of 54.5, 7.7 above uncontrolled patients (P=0.170).
In plain wordsIn pasireotide-treated Cushing's disease, partially controlled patients had adjusted quality-of-life scores 7.7 higher than uncontrolled patients at month 12 (P=0.170).
Peptide
Pasireotide
Outcome
IncreaseAdjusted CushingQoL, partially controlled versus uncontrolled
Study
n: not reported in source
Comparator
Uncontrolled mUFC at month 6
Outcome group
Quality of life · Whole body
Studied dose
600 or 900 μg twice daily · subcutaneousAs given in this study (human).
Measurements
Adjusted CushingQoL score
54.5 points
partially controlled mUFC at month 6, month 12
Difference versus uncontrolled
7.7 points
partially controlled versus uncontrolled
P value
0.17
partially controlled versus uncontrolled
Source sentences
Summary
Adjusted CushingQoL scores at month 12 were 58.3 for controlled patients (Δ=11.5 vs uncontrolled, P=0.012) and 54.5 for partially controlled patients (Δ=7.7 vs uncontrolled, P=0.170).
6 context sentences(design, population, supporting numbers)
Summary · context
In this phase III, randomized, double-blind study, patients with UFC ≥1.5×upper limit of normal (ULN) received s.c. pasireotide 600 or 900 μg twice daily.
Summary · context
Open-label treatment continued through month 12.
Summary · context
HRQOL was measured using the Cushing's Quality of Life Questionnaire (CushingQoL) instrument at baseline and follow-up visits until month 12 during which clinical signs and features of CD, and the Beck Depression Inventory II (BDI-II), were also collected.
Summary · context
Pearson's/Spearman's correlations between changes in CushingQoL and changes in clinical signs and symptoms were assessed.
Summary · context
Changes in CushingQoL and the proportion of patients achieving a clinically meaningful improvement in CushingQoL were also compared among patients stratified by mean UFC (mUFC) control status (controlled, partially controlled, and uncontrolled) at month 6.
Summary · context
Analyses were also conducted at month 12, with multivariable adjustment for baseline characteristics and CushingQoL.
Report a problemFND-2476053709

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.